Stelara’s Shift From Medicare B To D Was Costly, OIG Finds, How Much Will IRA Reforms Help?

The analysis was released days before the Biden Administration is expected to announce a reduced Medicare Part D price for Johnson & Johnson’s immunosuppressant resulting from the government negotiation program established by the Inflation Reduction Act.